Archives: Speakers

Scott Arnett is Senior Vice President of Global Enterprise Sales at Ericsson, where he leads a worldwide organization focused on helping enterprises accelerate digital transformation through advanced connectivity solutions, including private 5G, wireless WAN, and neutral host networks. Scott works closely with global customers, strategic partners, and industry leaders to modernize operations, improve resilience, and unlock new business outcomes across various industries. With deep experience in enterprise networking and digital infrastructure, he is passionate about helping organizations leverage next-generation wireless technologies to solve complex business challenges and drive innovation at scale.

Manfred Weiler is Head of Strategic Partnerships Pharma and Biotech’s for the EMEA region at Syneos Health. Dr. Manfred Weiler is a life sciences executive with more than 20 years of experience working with biotech and pharmaceutical customers within US, Europe and Asia. Through leadership roles in business development, alliance management, and medical strategy, he has built partnerships across the industry and seen how companies’ approaches to clinical development and outsourcing have evolved over the past two decades. He holds a PhD in molecular biology from the University of Bonn.

A strategic healthcare and innovation leader with 30 years of executive experience across public administration, life sciences, and philanthropy. Currently Head of Strategy and Partnerships at the DATA for GOOD Foundation, their previous roles include Academic Director at the Danish Diabetes Association, Director of APOVAC, and Deputy Director within the Capital Region of Denmark. They have directed multi-billion-kroner healthcare initiatives, notably the establishment of the Steno Diabetes Center Copenhagen (DKK 3 billion), the creation of Denmark’s national clinical-trial alliance Trial Nation, and the founding of the Eastern Denmark EU Office. Their earlier career includes policy roles at the Danish Ministry of Science and Ministry of Business, as well as private-sector management at F.L. Smidth A/S.

Prof. Dr. med. Ulf Forssmann is a physician-scientist and senior biopharmaceutical leader with more than 25 years of experience spanning translational medicine, clinical pharmacology, early clinical development, and oncology drug development. His career has focused on translating innovative biology into differentiated medicines and advancing novel therapeutic concepts from preclinical development through first-in-human studies and proof of concept.

He is currently Vice President, Medical Head of Early Development at Genmab, where he provides strategic medical leadership across the early development portfolio. His work spans multiple therapeutic modalities, including immuno-oncology, bispecific antibodies, antibody-drug conjugates, and next-generation antibody technologies. He has contributed to the clinical development of programs including acasunlimab (PD-L1x4-1BB), HexaBody-DR5/DR5, enapotamab vedotin, and several emerging immuno-oncology programs.

Before joining Genmab, Ulf held senior roles in exploratory medicine, oncology, and clinical pharmacology at Bayer Pharma and Merck Serono/Merck KGaA. Across these positions, he led multidisciplinary international teams and early development strategies covering cancer immunotherapy, bispecific antibodies, antibody-drug conjugates, cancer vaccines, immunocytokines, kinase inhibitors, and other targeted therapies. His scientific roots are in immunology, chemokine biology, and translational pharmacology.

Ulf is an Associate Professor at Hannover Medical School and has authored and co-authored numerous peer-reviewed publications spanning immunology, inflammation, translational research, and oncology. His recent work reflects a strong focus on the clinical translation of next-generation antibody therapeutics and on understanding how target biology, pharmacology, and biomarker strategies can inform early development decisions.

Today, his work sits at the intersection of science, medicine, and portfolio strategy. He is particularly passionate about building strong translational bridges between discovery and the clinic, designing development strategies that generate early biological and clinical insight, and advancing innovative therapeutics that can deliver meaningful benefit for patients with cancer.

Dr. Steven Cha is a hematologist-oncologist and bone marrow transplant physician with fellowship training at Stanford University with more than 20 years of oncology and hematology drug development experience. At Novotech, he guides medical and clinical development strategy for oncology programs. He previously held senior leadership roles including Chief Medical Officer and Senior Vice President of Oncology.

His experience spans first-in-human through Phase III studies in solid tumors and hematologic malignancies. He has worked across targeted therapies, immuno-oncology, antibody-drug conjugates, and cell therapies, with particular expertise in dose selection, biomarker strategy, early proof of concept, and global development planning. Drawing on sponsor-side experience in the United States, Asia-Pacific, and Europe, he helps teams design studies that answer the next clinical and regulatory question.

Strategy and operations consultant specializing in clinical and commercial biopharma supply chains, with expertise in launch readiness and end-to-end execution.

I am a highly dynamic leader with almost 20 years experience leading clinical operations teams across the APAC and EMEA regions within big pharma and biotech.

As Cluster Head Emerging Markets at BeOne, I successfully established a strategy to support EMEA portfolio growth by critically assessing cluster capabilities, expanding to new markets and growing talent pools. Under my leadership, my team of talented individuals spread across 16 diverse markets in Northern Europe, Eastern Europe, Middle East and Africa, has been responsible for approximately 30% of the enrolment contributions to the regional portfolio of global clinical trials in EMEA.

My innovative and forward thinking approach to clinical trial delivery, along with my passion for leading high performing teams to success, lends itself well to successful portfolio delivery in highly diverse and complex environments.